Sugen Uses Pangea's Tools To Reduce Redundancies

Dec 03, 1999

Premium

OAKLAND, Calif.--Sugen, a small molecule drug-discovery company wholly owned by Pharmacia and Upjohn, has licensed Pangea Systems' proprietary Clustering and Alignment Tools. Greg Plowman, Sugen's vice-president of molecular biology, said that the performance of Pangea's clustering tool on multiprocessor machines would allow Sugen to reduce the redundancies in its large sequence databases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Refined Risk Prediction

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

Shutdown and the FDA

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

This Week in PNAS

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

Influences from Here and There

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu